Belly Fat May Be an Independent Risk Factor for Psoriasis, Study Suggests

The relationship was particularly pronounced in women

by Kate Kneisel, Contributing Writer, MedPage Today
May 28, 2025 • 4 min read

Key Takeaways

  • The established role of obesity in psoriatic disease remains to be clearly defined.
  • Among 25 different measures of adiposity, abdominal fat was significantly associated with a risk for psoriasis.
  • This association was particularly notable for women.

Among 25 different measures of adiposity, abdominal fat was significantly associated with a risk for psoriasis, particularly among women, a cross-sectional study suggested.

Using data on 336,806 participants in the U.K. Biobank of white British ancestry, including 9,305 with psoriasis, four measures of central adiposity had the largest effect size for an association with psoriasis: waist-to-hip ratio (OR 1.26, P<0.00001), abdominal fat ratio (OR 1.24, P<0.00001), total abdominal adipose tissue index (OR 1.22, P<0.00001), and waist circumference (OR 1.23, P<0.00001), reported Catherine Smith, MD, of St John’s Institute of Dermatology at King’s College London, and colleagues in the Journal of Investigative Dermatology.

“The relationship between central adiposity and psoriasis was particularly pronounced in females, with larger effect sizes observed across several measures compared with those in males,” the group noted. For instance, visceral adipose tissue mass had a stronger association in women (interaction with sex P=0.0067).

“Our research shows that where fat is stored in the body matters when it comes to psoriasis risk. Central fat — especially around the waist — seems to play a key role,” said co-author Ravi Ramessur, MBBS, also of King’s College London, in a statement. “The observed links between central body fat and psoriasis suggest that there may be underlying biological mechanisms contributing to the disease that are not yet fully understood and which warrant further investigation.”

Interaction analyses to identify potential associations between adiposity measures and psoriasis polygenic risk scores (both including and excluding HLA-C*06:02) showed that full psoriasis polygenic risk scores were significantly associated with waist-to-hip ratio (P=0.047).

However, the interaction effect was no longer significant when HLA-C*06:02 was excluded from the polygenic risk score (P=0.141), “suggesting that the presence of HLA-C*06:02 has a major contribution to the significant interaction effect observed with the full psoriasis polygenic risk score,” Smith and team explained.

“In line with these findings, waist-to-hip ratio was associated with psoriasis with a significantly larger effect size in HLA-C*06:02-negative versus HLA-C*06:02-positive participants … consistent with previous observations,” they added.

Conversely, full psoriasis polygenic risk score with percentage body fat was not significantly linked with psoriasis risk (P=0.314), which the authors noted “may reflect differences in measurement precision rather than differences in biological relevance of central adiposity in psoriasis risk.”

“These findings have important translational implications for both clinical practice and public health,” they concluded. “The strong association between central adiposity and psoriasis, independent of genetic risk, suggests that waist-to-hip ratio could serve as a useful marker for identifying individuals at higher risk of psoriasis, including those at risk of more severe disease.”

He also pointed to the emerging interest in treating psoriatic disease with GLP-1 receptor agonists. “Indeed, GLP-1 receptor agonists have been shown to modulate key inflammatory pathways (IL-17 and TNFα) that drive psoriasis activity, GLP-1 receptors are over expressed in psoriasis plaques, and psoriasis is reported to improve in patients undergoing GLP-1 receptor agonist therapy.”

For this study, Smith and colleagues used data for 336,806 participants in the U.K. Biobank (180,714 women) to evaluate 25 approaches to assessing adiposity, including anthropometric, bioelectric impedance, and imaging-based measures (dual-energy x-ray absorptiometry and MRI).

They acknowledged limitations to their study, including the inability to generalize the findings beyond individuals of white British ancestry, and a lack of dermatologist confirmation of the psoriasis diagnosis.


Disclosures

This work was supported by Pfizer.

Smith reported grants from an MRC-funded stratified medicine consortium with multiple industry partners; grants from an IMI (Horizon 2020)-funded European consortium with multiple industry partners; and others from AbbVie, Novartis, Pfizer, Sanofi, Boehringer Ingelheim, and SOBI. She is also chair of U.K. guidelines on biologic therapy in psoriasis.

Several co-authors also reported relationships with industry.

Gelfand served as a consultant for AbbVie, Artax, BMS, Boehringer Ingelheim, Celldex, FIDE (which is sponsored by multiple pharmaceutical companies), GSK, Inmagene, Lilly, Leo, MoonLake, Janssen Biologics, Novartis, UCB, Neuroderm, and Oruka, receiving honoraria; receives research grants (to the Trustees of the University of Pennsylvania) from Amgen, BMS, and Pfizer; and received payment for continuing medical education work related to psoriasis that was supported indirectly by pharmaceutical sponsors. He is also deputy editor for the Journal of Investigative Dermatology, receiving honoraria from the Society for Investigative Dermatology; is chief medical editor for Healio Dermatology (receiving honoraria); and is a member of the Board of Directors for the International Psoriasis Council and the Medical Dermatology Society, receiving no honoraria.

Primary Source

Journal of Investigative Dermatology

Source Reference: Ramessur R, et al “Investigating the genetic basis of the influence of adiposity on psoriasis: a cross-sectional study in a large United Kingdom population-based Biobank” J Invest Dermatol 2025; DOI: 10.1016/j.jid.2025.03.024.

Secondary Source

Journal of Investigative Dermatology

Source Reference: Gelfand JM “The visceral relationship of psoriasis and obesity” J Invest Dermatol 2025; DOI: 10.1016/j.jid.2025.04.013.

Story Source

 

Comments Are Closed